Research programme: HDL cholesterol therapies - Pfizer/Xenon

Drug Profile

Research programme: HDL cholesterol therapies - Pfizer/Xenon

Alternative Names: HDL cholesterol therapies research programme - Pfizer/Xenon

Latest Information Update: 05 Jul 2004

Price : $50

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Low HDL cholesterol

Most Recent Events

  • 29 Jun 2004 Xenon Genetics is now called Xenon Pharmaceuticals
  • 30 May 2003 Discontinued - Preclinical for Low HDL cholesterol in Canada (unspecified route)
  • 01 Jul 2002 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top